Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Return on Sales (2022 - 2025)

Bioregenx (BRGX) has 4 years of Return on Sales data on record, last reported at 0.16% in Q3 2025.

  • For Q3 2025, Return on Sales rose 50.0% year-over-year to 0.16%; the TTM value through Sep 2025 reached 9.81%, down 794.0%, while the annual FY2024 figure was 9.85%, 965.0% down from the prior year.
  • Return on Sales reached 0.16% in Q3 2025 per BRGX's latest filing, up from 0.4% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.0% in Q2 2023 and bottomed at 39.96% in Q4 2024.
  • Average Return on Sales over 4 years is 3.91%, with a median of 0.62% recorded in 2022.
  • Peak YoY movement for Return on Sales: plummeted -3975bps in 2024, then surged 522bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 0.62% in 2022, then surged by 67bps to 0.21% in 2023, then plummeted by -19346bps to 39.96% in 2024, then surged by 100bps to 0.16% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.16% in Q3 2025, 0.4% in Q2 2025, and 0.52% in Q1 2025.